Endogenous Natriuretic Peptides Participate in Renal and Humoral Actions of Acute Vasopeptidase Inhibition in Experimental Mild Heart Failure

Mild heart failure is characterized by increases in atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in the absence of activation of the renin-angiotensin-aldosterone system (RAAS). Vasopeptidase (VP) inhibitors are novel molecules that coinhibit neutral endopeptidase 24.11, whic...

Full description

Saved in:
Bibliographic Details
Published in:Hypertension (Dallas, Tex. 1979) Tex. 1979), 2001-08, Vol.38 (2), p.187-191
Main Authors: Chen, Horng H, Lainchbury, John G, Matsuda, Yuzuru, Harty, Gail J, Burnett, John C
Format: Article
Language:English
Subjects:
Angiotensin-Converting Enzyme Inhibitors - pharmacology
Animals
Antihypertensive agents
Atrial Natriuretic Factor - physiology
Biological and medical sciences
Blood Pressure - drug effects
Cardiovascular system
Cyclic GMP - blood
Cyclic GMP - urine
Dogs
Fosinopril - analogs & derivatives
Fosinopril - pharmacology
Glomerular Filtration Rate - drug effects
Heart Failure - blood
Heart Failure - physiopathology
Heart Failure - urine
Male
Medical sciences
Neprilysin - antagonists & inhibitors
Pharmacology. Drug treatments
Polysaccharides - pharmacology
Protease Inhibitors - pharmacology
Pyridines - pharmacology
Receptors, Atrial Natriuretic Factor - antagonists & inhibitors
Sodium - urine
Thiazepines - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mild heart failure is characterized by increases in atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in the absence of activation of the renin-angiotensin-aldosterone system (RAAS). Vasopeptidase (VP) inhibitors are novel molecules that coinhibit neutral endopeptidase 24.11, which degrades the natriuretic peptides (NPs) and ACE. In a well-characterized canine model of mild heart failure produced by ventricular pacing at 180 bpm for 10 days, we defined the renal and humoral actions of acute VP inhibition with omapatrilat (OMA, n=6) and acute ACE inhibition (n=5) alone with fosinoprilat. We also sought to determine whether the NPs participate in the renal actions of acute VP inhibition by the administration of OMA together with an intrarenal administration of the NP receptor antagonist HS-142-1 (n=5). OMA resulted in a greater natriuretic response than did ACE inhibition in association with increases in plasma cGMP, ANP, BNP, urinary cGMP, urinary ANP excretion, and glomerular filtration rate (P
ISSN:0194-911X
1524-4563
DOI:10.1161/01.HYP.38.2.187